YouScript, Inc.

Seattle,  WA 
United States
http://Youscript.com
  • Booth: 823

At YouScript, our mission is to save lives, improve patient care and reduce costs by eliminating avoidable adverse drug events. Based on over 14,000 curated references, our patented medication management system is the only commercially available tool to assess the cumulative effect of a patient’s genetics and entire drug regimen. Our tools are used by value-based healthcare organizations, providers, and payers interested in bending the healthcare cost curve with the power of precision medicine.


 Press Releases

  • December 20, 2016 (Seattle, WA) -- YouScript Inc., today announced that well-regarded health IT industry professional Mike Issac has joined the team as Executive Vice President of Implementation. In this role, Issac will work closely with YouScript internal teams to oversee the successful implementation of the YouScript software at top medical centers using Epic, Cerner, AthenaHealth, and other EHR and healthcare software applications.

    “This is just the talent YouScript needed on the team to bring precision medicine to the point of care at the top medical centers in the country,” said Kristine Ashcraft, CEO of YouScript. “With almost 20 years’ experience in software implementation and integration with top national players, Mike is poised to make a direct impact on our business and on healthcare improvement, offering insight, expertise, and providing clients with excellent service.”

    Issac is an expert in providing support to sales, customer service, and technical teams in the healthcare industry. Issac joins YouScript from RemitDATA where he most recently served as a Senior Vice President after a successful transition and acquisition of co-ownership in IF Technologies. Previously, Issac was also the Vice President, Implementation Services at Bridge Medical who was acquired by Cerner and Medsphere Systems Corporation.

    YouScript is the leader in gene-based precision prescribing. In a study published in the Journal of Medical Economics, the University of Utah showed that the use of pharmacogenetic testing and YouScript’s clinical decision support software reduced hospitalizations by 39-percent and ER visits by 71-percent in elderly patients taking multiple medications in just 4-months. A pending publication of a randomized controlled trial in home health patients shows dramatic reductions in re-hospitalizations, ER visits, and mortality. Mike Issac stated, “This is one of the few solutions I have seen that meets the goals of the Triple Aim. I am excited to be on the team bringing this transformational technology to market.”

     

    About YouScript

    YouScript’s patented Personalized Prescribing System is the only medication management system to assess the total effect of a patient’s genetics and complete drug regimen. YouScript is used by healthcare providers, payors, genomics labs, pharmacies, and accountable care organizations. YouScript helps customers identify which patients are at the highest risk of adverse drug events, which ones would benefit from pharmacogenomic testing, and what clinicians can do to optimize the safety and effectiveness of medications. Based on over 14,000 curated references and product inserts, YouScript determines the cumulative impact of genetics, medications, over-the-counters, herbals, and other factors offering ranked alternatives when interaction risk is found. For more information, visit: www.youscript.com.

    ###

    Press contact:

    Jennifer Hayes
    YouScript
    jhayes@youscript.com
    206-826-1921

  • Use of pharmacogenetic testing supported by an appropriate clinical decision support tool reduces mortality and overall health resource utilization in patients treated with multiple medications

    Seattle, WA -- YouScript, a proprietary clinical decision support tool designed to assist in medication therapy management, has been shown to reduce readmissions by 52 percent (p=0.007) and ER visits by 42 percent (p=0.045) in patients over 50 taking multiple medications when combined with pharmacogenetic testing.

    Researchers at Harding University and Unity Health-White County Medical Center, in collaboration with Genelex Labs, a pioneer in pharmacogenomic testing, and precision prescribing software company, YouScript, conducted a randomized controlled trial in a high-risk population of chronically ill polypharmacy patients aged 50 years and older admitted to home health care after an in-patient hospitalization. The trial was designed to incorporate pharmacogenetic data into an integrated clinical decision support system and compare the results to a standard drug information system.

    This study validates the results of the IMPACT study completed by the University of Utah in 2015 in which hospitalizations were reduced 39% and ER visits 79% in elderly polypharmacy patients in an ambulatory environment in 4-months. In addition to re-hospitalization and ED visit metrics; the new study examined secondary endpoints including death and Medicare administrative quality measures. Risk of death decreased by 85 percent (p=0.05) compared to the control group and researchers estimated a potential per capita cost savings of $4,382 based upon Medicare average all-cause readmission and ER visit cost in only 60-days. The results of the study were recently published in PLOS ONE.

    “If reproduced across the entire Medicare home health population, this would save billions of dollars and thousands of lives every year. Not only does this meet the goals of the Triple Aim, but it brings to bear the question, when does it become a patient safety issue for this not to be part of the standard of care for polypharmacy patients,” said Kristine Ashcraft, CEO of Seattle-based YouScript. “We appreciate all the hard work Harding University has done and thank the patients at Unity Health’s White County Medical Center for their participation in this landmark study validating the power of precision medicine.”

    The study examined two groups of 50-and-older home health patients taking an average of 11.6 prescription drugs. The mean Outcome and Assessment Information Set (OASIS) score for overall health at the start of intervention, drug count at baseline, and pharmacogenetic risk, the likelihood that testing would reveal substantial gene based drug interactions, in the tested and untested groups were the same. The study population was selected to have a higher than average return on pharmacogenetic testing defined by the likely frequency of drugs interacting with cytochromes or CYPs, enzymes in the liver that metabolize many medications. Drugs are currently prescribed assuming normal genetics for the CYPs when only 7% of patients are normal for all five of the main CYPs.

    •    The tested group received a physician order for Genelex pharmacogenetic testing followed by a study pharmacist reviewing drug-drug, drug-gene, and cumulative drug and/or gene interactions in the tested group using YouScript generated reports and clinical decision support tool to provide drug therapy recommendations to clinicians, after which prescriptions were altered at clinician discretion.

    •    The second group, a matched untested control group, received treatment as usual including pharmacist guided medication management using a standard drug information resource.

    The primary outcome measures were the number of readmissions and ER visits at 30 days and 60 days after discharge from the hospital.  These findings occurred in a Home Health Agency (HHA) that, according to 2015 Home Health Quality Improvement reporting was already in the 5th - 12th percentile CMS benchmark group for lowest readmissions.

     Lindsay S. Elliott, Pharm.D., BCGP who was the primary investigator for the study noted, "All clinicians strive to improve quality of life for their patients. Knowing patient specific drug metabolism combined with the ability to identify cumulative drug-drug, drug-gene, and drug-drug-gene interactions will only aid in our efforts. This study demonstrates the potential to manage medication regimens specific to the patient in order to increase efficacy, decrease adverse effects, and reduce overall healthcare costs."

    The YouScript system combines comprehensive predictive medication management analytics with pharmacogenetic testing to provide an at-a-glance summary of how the complex web of medication and genetic interactions affect patient response to drug treatments. The patented software algorithms analyze patient medication regimens combined with genetic test results to predict the potential for adverse drug events and treatment failures. When potential problems are identified, YouScript suggests alternative medications with reduced interaction risk, taking into account all other relevant drugs, herbals, and genetic factors.

     “Randomized controlled trials of integrated pharmacogenetic information in a broad polypharmacy population have been lacking. The data from this study offers a potentially important opportunity to minimize ADEs and reduce health resource utilization,” said corresponding author Ranjit Thirumaran, M.Pharm, Ph.D., Director, Clinical Pharmacogenetics at YouScript.

    #   #   #

    About Genelex
    Founded in 1987, Seattle-based Genelex is one of the first clinical laboratories to provide pharmacogenetic testing and interpretation. Pharmacogenetic testing examines variations of the cytochrome P450 (CYP) enzymes. While there are over 50 CYP enzymes, approximately five contribute to the metabolism of over 80 percent prescription medications, herbals, and over the counter medications. The Genelex pharmacogenetic test reveals natural variations present in more than 90 percent of people that determine how the body processes commonly prescribed medications. As creators of the patented and proprietary YouScript Personalized Prescribing System, Genelex is a pioneer in comprehensive medication analytics and pharmacogenetic testing.

    For more information, visit: www.genelex.com.

    About YouScript
    Based on fifteen years of technology development that makes precision prescribing possible, Seattle-based YouScript was founded in 2016 after spinning out of Genelex. The YouScript clinical decision support tool is the only medication management system available that assesses the cumulative effect of a patient drug regimen and unique pharmacogenomic results. Based on over 14,000 curated references and product inserts, YouScript uses comprehensive predictive analytics to interpret and provide an at-a-glance summary of the complex web of genetics, medications, over-the-counters, herbals, and other factors impacting drug safety and response; identifying at risk patients for testing and offering ranked alternatives with reduced interaction risk whenever an adverse interaction risk is found.

    For more information, visit: www.youscript.com or HIMSS Booth #823.

    Contact:
    Jennifer Hayes
    Phone: 206.826.1921
    Email: jhayes@youscript.com

 For technical assistance with this webpage please: Click Here For all other inquiries, please contact show management.